2016
DOI: 10.5582/irdr.2016.01007
|View full text |Cite
|
Sign up to set email alerts
|

New perspective on molecular markers as promising therapeutic targets in germ cell tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2018
2018
2019
2019

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 29 publications
0
3
0
Order By: Relevance
“…These three drugs have similar potency versus Aurora A, and Aurora B. Each induces a similar phenotype in cell-based assays, characterized by inhibition of phosphorylation of histone H3 on Ser 10 and Ser 28 , inhibition of cytokinesis, and development of polyploidy (28)(29)(30)(31)(32)(33)(34).…”
Section: Aurora B As Therapeutic Targetmentioning
confidence: 99%
See 1 more Smart Citation
“…These three drugs have similar potency versus Aurora A, and Aurora B. Each induces a similar phenotype in cell-based assays, characterized by inhibition of phosphorylation of histone H3 on Ser 10 and Ser 28 , inhibition of cytokinesis, and development of polyploidy (28)(29)(30)(31)(32)(33)(34).…”
Section: Aurora B As Therapeutic Targetmentioning
confidence: 99%
“…However, antimitotic drugs frequently show the appearance of drug resistance, adverse side effects (neurotoxicity) and their clinical effects are not predictable. Aurora inhibitors lack neurotoxicity and could contribute to the treatment of human neoplasia (31)(32)(33)(34).…”
Section: Aurora B and Cancermentioning
confidence: 99%
“…Numerous new biomarkers have been found to discriminate TGCTs subtypes, standing for innovative molecular therapeutic targets. High-mobility group proteins A1 (HMGA1) and A2 (HMGA2) act as powerful diagnostic markers (12)(13)(14)(15). Really, these two proteins are diversely expressed in TGCTs in comparison with the stage of tumor differentiation (12,13).…”
mentioning
confidence: 99%